Skip to main content
Clinical Trials/NCT07538284
NCT07538284
Not yet recruiting
Phase 2

Minimizing Delirium With Nasal Dexmedetomidine-Induced Sleep in Older Patients Undergoing Major Abdominal Surgery: : a Randomized, Double-blind, Placebo-controlled Trial

Sixth Affiliated Hospital, Sun Yat-sen University0 sites400 target enrollmentStarted: May 1, 2026Last updated:

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Enrollment
400
Primary Endpoint
Incidence of postoperative delirium

Overview

Brief Summary

This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.

Detailed Description

Delirium is an acute, short-term brain dysfunction characterized by fluctuating consciousness, cognitive decline, inattention, and sleep-wake cycle disruption. Postoperative delirium (POD), occurring predominantly within the first postoperative week (especially days 3-5 in elderly patients), affects 11-45% of older adults after major surgery. POD prolongs hospitalization, increases morbidity and mortality 5,65,6, yet its pathophysiology remains unclear, and evidence-based pharmacological prevention is lacking. Thus, effective POD prevention strategies are urgently needed.

Preoperative anxiety, a modifiable risk factor for POD, affects 11-80% of surgical patients. It contributes to sleep disturbances (e.g., insomnia, early awakening), which may exacerbate POD via neuroendocrine and immune dysregulation. However, benzodiazepines (e.g., lorazepam, diazepam, midazolam), though effective anxiolytics, increase delirium risk and are contraindicated preoperatively per current guidelines.

Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, induces physiological non-REM sleep without respiratory depression or hemodynamic instability. Its nasal formulation offers high bioavailability (82%), ease of administration, and is approved in China for preoperative sedation/anxiety. While intravenous (IV) DEX reduces POD in predominant ICU settings, its use in general wards remains unexplored. Preclinical studies suggest DEX enhances glymphatic clearance and exerts anti-inflammatory effects, potentially mitigating the development of POD. This study thus hypothesize that a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patient population. We set to demonstrate that to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in older patients undergoing major abdominal surgery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
65 Years to 90 Years (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged 65-90 years
  • Scheduled for a major abdominal surgery with estimated surgery time ≥ 2 hours

Exclusion Criteria

  • Blind, deafness or the inability to speak mandarin
  • Allergy to dexmedetomidine.
  • Renal and liver failure requiring dialysis or Child-Pugh score \> 5
  • Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)
  • Previous major abdominal or cardiac surgery within 1 year of surgical procedure
  • Chronic therapy with benzodiazepines and/or antipsychotics. Severe deficit due to structural or anoxic brain damage
  • Body weight \< 35 kg

Arms & Interventions

Placebo

Placebo Comparator

Intervention: Placebo (Drug)

Dexmedetomidine

Experimental

Intervention: Dexmedetomidine (Drug)

Outcomes

Primary Outcomes

Incidence of postoperative delirium

Time Frame: Up to postoperative day (POD) 7 or discharge (whichever first).

Confusion Assessment Method

Secondary Outcomes

  • Delirium severity(Up to postoperative day (POD) 7 or discharge (whichever first))
  • Physical activity(Up to postoperative day (POD) 3)
  • Sleep quality(Up to postoperative day (POD) 3)
  • Anxiety(Up to postoperative day (POD) 3)
  • Pain intensity(Up to postoperative day (POD) 3)
  • Opioid consumption(Up to postoperative day (POD) 3)
  • Health related quality of life(On postoperative day (POD) 3 and 30)
  • Quality of Recovery(Up to postoperative day (POD) 3)
  • Postoperative Nausea and Vomiting(Up to postoperative day (POD) 3)
  • Post-anesthesia Care Unit (PACU) length of stay(Up to postoperative day (POD) 1)

Investigators

Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xiangcai Ruan, MD, PhD

Professor

Sixth Affiliated Hospital, Sun Yat-sen University

Similar Trials